「デジタルトランスフォーメーション銘柄（DX銘柄）2026」選定のお知らせ
中外製薬株式会社 （本社：東京、代表取締役社長 CEO：奥田 修）は、このたび、経済産業省、東京証券取引所及び独立行政法人情報処理推進機構が選定する「デジタルトランスフォーメーション銘柄（DX銘柄）2...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
中外製薬株式会社 （本社：東京、代表取締役社長 CEO：奥田 修）は、このたび、経済産業省、東京証券取引所及び独立行政法人情報処理推進機構が選定する「デジタルトランスフォーメーション銘柄（DX銘柄）2...
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical News
Scope: Industry
Related coverage
More related coverage
Pharma Research & Development
Pharma Research & Development
Pulse Biosciences hires Liane Teplitsky as COO
Chugai Selected as “Digital Transformation Stocks (DX Stocks) 2026&rdquo
TOKYO, April 10, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it has b...
Shionogi Selected as a “DX Stock 2026”
The DX Stock program evaluates and selects companies that are transforming their business models and...